Nasal Cavity and Paranasal Sinus CancerNCT07512466
Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations
A study testing endoscopic approch in people with Nasal Cavity and Paranasal Sinus Cancer, run by Assiut University.
Trial summary
Research outcome measures: 1. Primary (main): To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas 2. Secondary (subsidiary): 1. Assess postoperative improvement in Quality of Life 2. Quantify intraoperative blood loss and surgical duration 3. Read more about this study
- Who is it for?
- Ages 1 year to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Nasal Cavity and Paranasal Sinus Cancer
- What is being tested?
- endoscopic approch
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 25 participants
- Where
- No sites listed yet
- Study dates
- Apr 2026to Apr 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 80 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- -Patients with sinonasal and nasopharyngeal tumors
Who cannot join
- Extensive lesions required open approach ex (intraconal extension need orbital exenteration).
- Absolute contraindications to general anaesthesia.
About this study
Research outcome measures:
- Primary (main): To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas
- Secondary (subsidiary):
- Assess postoperative improvement in Quality of Life
- Quantify intraoperative blood loss and surgical duration
- Document the incidence of complications (CSF leak, nerve palsy, vascular injury)
Read the detailed description
Sinonasal tumors are a heterogeneous group of neoplasms arising from the nasal cavity and paranasal sinuses, representing a rare subset of head and neck tumors. Tumors arising from the sinonasal cavity can be subdivided into benign and malignant characters .Sinonasal malignancy are rare, representing <1% of all malignancies and <5% of head and neck cancers.Benign sinonasal tumors are more common than malignant lesions and include inverted papilloma, hemangioma, osteoma, juvenile nasopharyngeal angiofibroma, and various fibrous and glandular neoplasms.(1)The sinonasal cavity includes the epithelial, mesenchymal, salivary gland, cartilaginous and osseous proponents, and as such, it may lead to various original malignancies including the squamous cell carcinoma (most common) and the others (adenocarcinoma, adenoid cystic carcinoma, sarcoma, olfactory neuroblastoma,).(2) Surgical resection is often the first step of the therapeutic strategy in treatment of sinonasal tumors, possibly combined with adjuvant therapies .Tumors at pterygopalatine and infratemporal fossae,sphenoid and maxillary sinus poses challenges to surgeons for their deep location and intimate relationship with highly functional neurovascular and osteo-muscular structures .(3)Tumors in these challenging regions were managed via invasive open surgical resection ,these interventions are frequently morbid, resulting in profound neurological and functional sequelae that adversely impact the patient's clinical outcomes.(4) Endoscopic endonasal surgery become a standard approach in the management of many benign and selected malignant sinonasal tumors .It is as a minimally invasive surgical alternative, facilitating access to difficult locations with preserving the osteo-ligamental and muscular structures with no visible scars, optimal cosmetic outcome, and consequently limited risk of permanent neurological or functional deficits.(5)
- Conditions
- Nasal Cavity and Paranasal Sinus Cancer
- Being tested
- endoscopic approch
- Medical subject headings
- Paranasal Sinus Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
endoscopic approchProcedure or surgery
mangment of endoscopic approch in sinonasal tumors excision
| Study group | Role | What they receive |
|---|---|---|
| endoscopic resection of sinonasal tumors | Experimental | Not described Receives: Procedure: endoscopic approch |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations
To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas
Measured: 4 years
percentage of complete resection post operative
complete resection of tumer by endoscopic approch
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2026
- Study startApr 2026 (estimated)
- Primary completionOct 2027 (estimated)
- Study completionApr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nasal Cavity and Paranasal Sinus CancerStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 25 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aya abdelnasser hassani, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07512466
- Sponsor's protocol ID
- EEA in sinonasal tumors
- Status last verified
- Apr 2026
- First submitted
- 17 Mar 2026
- Last updated
- 6 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 6 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations
- ClinicalTrials.gov ID
- NCT07512466
- Acronym / sponsor ID
- EEA in sinonasal tumors
- Conditions
- Nasal Cavity and Paranasal Sinus Cancer
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 25 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- Apr 2026 (estimated)
- Primary completion
- Oct 2027 (estimated)
- Study completion
- Apr 2028 (estimated)
- First posted
- 6 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Research outcome measures:
- Primary (main): To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas
- Secondary (subsidiary):
- Assess postoperative improvement in Quality of Life
- Quantify intraoperative blood loss and surgical duration
- Document the incidence of complications (CSF leak, nerve palsy, vascular injury)
Detailed description
Sinonasal tumors are a heterogeneous group of neoplasms arising from the nasal cavity and paranasal sinuses, representing a rare subset of head and neck tumors. Tumors arising from the sinonasal cavity can be subdivided into benign and malignant characters .Sinonasal malignancy are rare, representing <1% of all malignancies and <5% of head and neck cancers.Benign sinonasal tumors are more common than malignant lesions and include inverted papilloma, hemangioma, osteoma, juvenile nasopharyngeal angiofibroma, and various fibrous and glandular neoplasms.(1)The sinonasal cavity includes the epithelial, mesenchymal, salivary gland, cartilaginous and osseous proponents, and as such, it may lead to various original malignancies including the squamous cell carcinoma (most common) and the others (adenocarcinoma, adenoid cystic carcinoma, sarcoma, olfactory neuroblastoma,).(2) Surgical resection is often the first step of the therapeutic strategy in treatment of sinonasal tumors, possibly combined with adjuvant therapies .Tumors at pterygopalatine and infratemporal fossae,sphenoid and maxillary sinus poses challenges to surgeons for their deep location and intimate relationship with highly functional neurovascular and osteo-muscular structures .(3)Tumors in these challenging regions were managed via invasive open surgical resection ,these interventions are frequently morbid, resulting in profound neurological and functional sequelae that adversely impact the patient's clinical outcomes.(4) Endoscopic endonasal surgery become a standard approach in the management of many benign and selected malignant sinonasal tumors .It is as a minimally invasive surgical alternative, facilitating access to difficult locations with preserving the osteo-ligamental and muscular structures with no visible scars, optimal cosmetic outcome, and consequently limited risk of permanent neurological or functional deficits.(5)
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| endoscopic resection of sinonasal tumors | Experimental | Procedure: endoscopic approch |
Who may qualify
- Ages
- 1 year to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- -Patients with sinonasal and nasopharyngeal tumors
Key exclusion criteria (2 listed)
- Extensive lesions required open approach ex (intraconal extension need orbital exenteration).
- Absolute contraindications to general anaesthesia.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| endoscopic approchmangment of endoscopic approch in sinonasal tumors excision | Procedure or surgery | endoscopic resection of sinonasal tumors |
Primary outcome
Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations
Time frame: 4 years
To Evaluate the Gross Total Resection Rate Using Endoscopic Approach for Lesions Extended To Anatomically Challenging Areas
percentage of complete resection post operative
Time frame: 2 years
complete resection of tumer by endoscopic approch
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Apr 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Nasal Cavity and Paranasal Sinus Cancer
RecruitingObservational study
SPARE-1st: Surgery Alone vs Surgery Plus Postoperative Radiotherapy for Sinonasal Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
RecruitingObservational study
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Esophageal Cancer, Head and Neck Cancer
RecruitingObservational study
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Active, not recruiting
Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy
Squamous Cell Carcinoma of Oral Cavity, Pharynx Carcinoma
Active, not recruitingPhase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing endoscopic approch in people with Nasal Cavity and Paranasal Sinus Cancer, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations (time frame: 4 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Apr 2026.